Blueshift Asset Management’s SpringWorks Therapeutics SWTX Stock Holding History

Blueshift Asset Management’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-9,096	Closed	-$401K	–	593
2025 Q1	$401K	Buy	+9,096	New	+$419K	0.16%	206
2022 Q2	–	Sell	-8,299	Closed	-$468K	–	991
2022 Q1	$468K	Buy	+8,299	New	+$475K	0.04%	472
2021 Q3	–	Sell	-5,882	Closed	-$485K	–	1290
2021 Q2	$485K	Buy	+5,882	New	+$447K	0.03%	577
2021 Q1	–	Sell	-4,801	Closed	-$348K	–	1065
2020 Q4	$348K	Buy	+4,801	New	+$309K	0.04%	496

Other funds holding SWTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Blueshift Asset Management's SWTX Position: Q2 2025 in Review

Blueshift Asset Management sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 9,096 shares — an estimated $401K sold.

Blueshift Asset Management first reported a position in SWTX in Q4 2020 and held it in 4 quarters. The position peaked at $485K in Q2 2021. 223 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

Blueshift Asset Management reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
Blueshift Asset Management sold 9,096 SpringWorks Therapeutics shares in Q2 2025, an estimated $401K.
Blueshift Asset Management first reported a position in SpringWorks Therapeutics in Q4 2020 and held it in 4 quarters.
Blueshift Asset Management's SpringWorks Therapeutics position peaked at $485K in Q2 2021.
223 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Blueshift Asset Management's 13F filing for Q2 2025, filed 13 Aug 2025.